As obesity treatment becomes increasingly personalized, clinicians are often choosing among several highly effective therapies rather than deciding whether to treat at all, said co-author Yuan Lu, Assistant Professor of Cardiology at Penn Considering blood pressure, cholesterol, and glucose control together could be key to aligning with each patients overall, individualized cardiometabolic profile. Three focal points for the future Chen identified a collection of priorities for the next phase of GLP-1 research and obesity care
Safety concerns include hyperglycemia, nausea, and hypokalemia risks
Tuy nhin, nu bn mun dng cht ny cho mt mc tiu c th, hy tham kho kin bc s c t vn v s dng ng cch bn nh.
J Endocrinol 248(3):325335
5 and 4.8 vs
As a GLP-1 receptor agonist, Ozempic is gaining increasing recognition for its superior effectiveness in supporting patients weight management journeys and helping them attain healthier lifestyles